Overview

A Safety and Efficacy Study of Ispronicline (TC-1734-112) in Subjects With Age Associated Memory Impairment (AAMI)

Status:
Completed
Trial end date:
2005-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase II study is to evaluate the efficacy and safety of ispronicline (TC-1734-112) compared to placebo (inactive substance pill) in patients with age associated memory impairment (AAMI). AAMI is characterized as cognitive impairment including memory loss and poor concentration associated with aging.
Phase:
Phase 2
Details
Lead Sponsor:
Targacept Inc.
Treatments:
Acetylcholine
Nicotinic Agonists